$CHRS News

Coherus Oncology: Setting Up For Important Readouts In Mid-2026

Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript

Coherus Oncology (NASDAQ:CHRS) Q1 Revenue Misses Estimates Despite LOQTORZI Growth

Coherus BioSciences Q1 Adj. EPS $(0.25) Beats $(0.27) Estimate, Sales $12.310M Miss $14.342M Estimate

Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates

Coherus Oncology Inc (NASDAQ:CHRS) Reports Mixed Q4 2025 Results as LOQTORZI Sales Grow

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Coherus Oncology: Q4 Earnings Snapshot

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Insights into Coherus Oncology Q4 Earnings

Coherus BioSciences Q4 Adj. EPS $(0.34), Inline, Sales $12.748M Miss $13.944M Estimate

Coherus Oncology Touts 90% Debt Cut, LOQTORZI Sales Surge, Sets 2026 Data Catalysts

Coherus BioSciences's Earnings Outlook

How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation Risks

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates